专利检索_ 疾病的检测或诊断专利检索_ 疾病的检测或诊断专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
121	Targets for regulation of angiogenesis	US12945298	2010-11-12	US08734789B2	2014-05-27	Nancy Klauber DeMore; Cam Patterson; Rajendra Bhati; Bradley G. Bone
The present invention relates to the identification of polynucleotides and polypeptides having increased expression in tumor blood vessels. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of angiogenesis and the diagnosis and treatment of angiogenesis-related diseases such as cancer.
122	Organ-Specific Proteins and Methods of Their Use	US14072651	2013-11-05	US20140106981A1	2014-04-17	Leroy Hood; Patricia M. Beckmann; Richard Johnson; Marcello Marelli; Xiaojun Li
The present invention relates generally to methods for identifying and using organ-specific proteins and transcripts. The present invention further provides compositions comprising organ-specific proteins and transcripts encoding the same, detection reagents for detecting such proteins and transcripts, and diagnostic panels, kits and arrays for measuring organ-specific proteins/transcripts in blood, biological tissue or other biological fluid.
123	Cancer cell migration and cancer cell invasion inhibitor	US12934133	2009-03-19	US08674079B2	2014-03-18	Kohsuke Gonda; Hideo Higuchi; Noriaki Ohuchi; Motohiro Takeda
Provided are an antibody which binds specifically PAR1 (protease activated receptor 1) or a fragment of the antibody which retains similar characteristics thereto; a composition containing the same for inhibiting the migration activity and invasion activity of cancer cells; and a medicinal composition for treating cancer and the like.
124	PEPTIDE APTAMERS AGAINST TENASCIN C	US13955537	2013-07-31	US20140030736A1	2014-01-30	Sun Joo JEONG; Mee Young Kim; Ok Ran Kim; Heui Ran Lee; Kee Rang Park
The present invention relates to an anti-tenascin C peptide aptamer having a specific amino acid sequence and a diagnosis kit comprising it. The anti-tenascin C peptide aptamer of the instant invention shows a predominant clearance rate due to its small molecular weight as well as specific binding affinity to tenascin C, having excellent advantages in in vivo or ex vivo tumor imaging.
125	METHOD OF IDENTIFYING, ISOLATING AND/OR CULTURING FOETAL ERYTHROBLASTS	US14111159	2012-04-11	US20140030724A1	2014-01-30	Chui Yee Fong; Ariffeen Bongso; Mahesh Choolani; Zhouwei Huang; Gauthaman Kalamegam; Sukumar Ponnusamy
There is provided a method of identifying at least one foetal erythroblast in a sample, the method comprising analysing the morphology of at least one cell in the sample; wherein at least one analysed cell that is nucleated, is CD45 negative and comprises a relatively high cytoplasmic to nuclear ratio is identified as the foetal erythroblast.
126	Screening method for cell aging	US13382629	2010-07-08	US08628922B2	2014-01-14	Elizabeth Jane Mellor; Michael Youdell; Anitha Nair; Alexandre Akoulitchev
The present invention relates to a method for increasing the chronological lifespan of a cell comprising disrupting the function of at least one of the SAGA1 SLIK and/or SALSA complexes in said cell.
127	Method for evaluating a set of measurement data from an oral glucose tolerance test	US13935151	2013-07-03	US20130297224A1	2013-11-07	Arnulf Staib; Ortrud Quarder; Gerhard Werner
A method is provided for evaluating a set of measurement data from an oral glucose tolerance test. The method may include calculating a similarity measure that quantifies the similarity between a time profile of the series of measured data of the glucose concentration and a corresponding glucose reference profile. The method may include calculating a further similarity measure that quantifies the similarity between the profile of the series of measured values of the further analyte concentration and the corresponding analyte sample profile, wherein the data set is represented by a point in a vector space that comprises coordinate axes that are formed by the similarity measures, whereby the coordinates of said point contain the calculated values of the similarity measures. The method also may include evaluating the position of the point with respect to reference points, which each represent a defined state of health, in order to calculate a parameter that specifies the state of the glucose metabolism of the patient.
128	METHODS OF VALIDATING CANDIDATE COMPOUNDS FOR USE IN TREATING COPD AND OTHER DISEASES	US13836332	2013-03-15	US20130273586A1	2013-10-17	Gerard M. TURINO; Shuren Ma; Yong Y. Lin; Seymour Leiberman
The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
129	Compositions And Methods For Modulating S-Nitrosogluthione Reductase	US13094091	2011-04-26	US20130196342A1	2013-08-01	Jonathan S. Stamler; Limin Liu
Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures for measuring, monitoring, or altering GSNOR levels or activity (as well as nitric oxide and S-nitrosothiol levels) in connection with various medical conditions.
130	Scavenger receptor	US12579968	2009-10-15	US08410253B2	2013-04-02	Nobutaka Wakamiya
Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper β-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypo α-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like. Also disclosed are methods for the treatment using the same.
131	RANTES Multiplexed Assay, RANTES Variants Related to Disease, and RANTES Variants Related to Enzymatice Activity	US13577638	2011-02-07	US20130053257A1	2013-02-28	Paul E. Oran; Randall W. Nelson
The present invention relates to multiplexed assays for the diagnosis of RANTES-based disorders. Essentially, a single, high information content RANTES assay is used to simultaneously determine an individual's disposition towards a disease as well as the onset and progression of the disease (or response to treatment). As such, the (single) analysis has the particular advantage of always producing data useful in the longitudinal monitoring (of individuals) for a disease. In specific example, the discovery relates RANTES isoforms with the predisposition, onset and progression of T2D, CHF, MI, and cancer. All isoforms of particular blood and urine borne proteins—containing protein phenotype data—are monitored in a single, high throughput analysis able to acquire data relevant to the stages of the disease (or treatment).
132	BIOMARKERS PREDICTIVE OF PROGRESSION OF FIBROSIS	US13505985	2010-11-04	US20120282276A1	2012-11-08	Cory Hogaboam; Steven L. Kunkel; Glenda Trujillo
The present invention provides methods and kits for prognosing the progression of fibrosis in a subject having fibrosis, as well as methods for identifying a compound that can slow down the progression of fibrosis in a subject having fibrosis, methods of monitoring the effectiveness of a therapy in reducing the progression of fibrosis in a subject having fibrosis, methods of selecting a subject for participation in a clinical trial for the treatment of fibrosis, and methods for inhibiting progression of fibrosis in a cell or a subject having fibrosis. The methods are based on determining the level of Toll-like recepter 9 (TLR9).
133	SCREENING METHOD FOR CELL AGING	US13382629	2010-07-08	US20120270213A1	2012-10-25	Elizabeth Jane Mellor; Michael Youdell; Anitha Nair; Alexandre Akoulitchev
The present invention relates to a method for increasing the chronological lifespan of a cell comprising disrupting the function of at least one of the SAGA1 SLIK and/or SALSA complexes in said cell.
134	Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease	US13002106	2009-06-30	US20110319499A1	2011-12-29	Richard David Semba; Luigi Ferruci; Edward G. Lakatta
The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease, hi particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes.
135	Methods and Compositions for Detection of a Pathogen, Disease, Medical Condition, or Biomarker Thereof	US13056486	2009-07-28	US20110306035A1	2011-12-15	Dorit Arad; Yaniv Nevo; Assaf Ezra
Provided are methods for detecting the presence or absence of a pathogen, disease, or medical condition, or biomarker thereof, using an enzymatic activity assay. In one embodiment, the method provided utilizes competitive inhibition of an enzyme for detecting a pathogen, disease, or medical condition, or biomarker thereof, in a subject. The method comprises providing a biological sample from the subject that may or may not contain an endogenous substrate. A test reaction is provided by contacting the biological sample with an enzyme indicative of the biomarker of a pathogen, disease, or medical condition and a substrate comprising a signaling moiety. The enzyme modifies the endogenous substrate and the substrate comprising the signaling moiety. Modification of the substrate comprising the signaling moiety by the enzyme produces a signal from the signaling moiety. Data from a control reaction comprising the enzyme and the substrate comprising the signaling moiety is further provided. The signal produced by the signaling moiety in the test reaction is detected. The presence of the biomarker of the pathogen, disease, or medical condition is indicated by a difference caused by the presence of the endogenous substrate in the biological sample between the signal produced in the test reaction and the data from the control reaction. In another embodiment, there is provide a method of detecting the presence or absence of enzymatic activity in a biological sample indicative of a pathogen, disease, or medical condition, or biomarker thereof, in a subject. The method comprises contacting a biological sample obtained from a subject that may or may not contain an enzyme with a substrate of the enzyme to be detected. The substrate comprises a signaling molecule such that when the enzyme is present in the biological sample, the enzyme modifies the substrate and the signaling moiety emits a signal, indicating the presence of a pathogen, disease, or a medical condition, or a biomarker thereof, in the subject.
136	FERROPORTIN ANTIBODIES AND METHODS OF USE	US12863737	2009-01-23	US20110274691A1	2011-11-10	Tara Arvedson; James Rottman; Barbra Sasu; Gregory Dyas
Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.
137	METHOD FOR DETERMINATION OF OXIDATIVE STRESS	US13092420	2011-04-22	US20110259743A1	2011-10-27	Tomoyoshi SOGA; Makoto Suematsu
Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.
138	METHOD FOR MEASURING HUMAN MEGALIN	US13093984	2011-04-26	US20110195523A1	2011-08-11	SHINYA OGASAWARA; SHUHEI MIURA; AKIHIKO SAITO; TETSURO TAKEDA
This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed.
139	CANCER CELL MIGRATION AND CANCER CELL INVASION INHIBITOR	US12934133	2009-03-19	US20110070163A1	2011-03-24	Kohsuke Gonda; Hideo Higuchi; Noriaki Ohuchi; Motohiro Takeda
Provided are an antibody which binds specifically PAR1 (protease activated receptor 1) or a fragment of the antibody which retains similar characteristics thereto; a composition containing the same for inhibiting the migration activity and invasion activity of cancer cells; and a medicinal composition for treating cancer and the like.
140	Methods for treating and preventing fibrosis	US11402885	2006-04-13	US07910105B2	2011-03-22	Deborah A. Young; Thomas A. Wynn; Mary Collins; Michael J. Grusby
The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).

2 3 4 5 6 7 8 9 10 11

该功能需要专业版企业版VIP权限，您可以：